Sutro Biopharma (STRO) Projected to Post Quarterly Earnings on Monday

Sutro Biopharma (NASDAQ:STRO - Get Free Report) is projected to announce its earnings results before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($0.86) per share and revenue of $12.18 million for the quarter.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last released its quarterly earnings data on Thursday, March 13th. The company reported ($2.96) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($2.10). Sutro Biopharma had a negative net margin of 77.01% and a negative return on equity of 101.89%. The company had revenue of $14.00 million during the quarter, compared to analyst estimates of $10.44 million. During the same quarter in the prior year, the company posted ($1.78) EPS. On average, analysts expect Sutro Biopharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Sutro Biopharma Stock Down 1.0 %

Shares of STRO traded down $0.01 during mid-day trading on Thursday, hitting $0.81. 1,598,444 shares of the company's stock were exchanged, compared to its average volume of 966,959. The firm has a fifty day moving average of $1.69 and a two-hundred day moving average of $2.66. Sutro Biopharma has a twelve month low of $0.76 and a twelve month high of $6.13. The stock has a market cap of $67.04 million, a price-to-earnings ratio of -0.50 and a beta of 1.22.

Remove Ads

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Piper Sandler set a $2.00 price target on shares of Sutro Biopharma in a research note on Friday, March 14th. Wedbush lowered shares of Sutro Biopharma from an "outperform" rating to a "neutral" rating and dropped their price target for the stock from $8.00 to $2.00 in a research note on Friday, March 14th. Citizens Jmp lowered shares of Sutro Biopharma from an "outperform" rating to a "market perform" rating in a research note on Friday, March 14th. Bank of America downgraded shares of Sutro Biopharma from a "buy" rating to an "underperform" rating and decreased their price objective for the stock from $11.00 to $1.00 in a report on Friday, March 14th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $17.00 price objective on shares of Sutro Biopharma in a report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $6.63.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.